Mild and moderate depressive symptoms: new data find Adonat®-SAMe helpful
DESIO, Italy - November 26th, 2018
A new clinical study shows the effects of a S-AdenosylMethionine-based dietary supplement (SAMe 200 mg/die - Adonat® SAMe ingredient manufactured by the biotech company Gnosis SpA - plus vitamin B-complex) in improving mild and moderate depressive symptoms.
The study included 60 patients randomly allocated into two groups. The study group was treated with SAMe-vitamin B complex while the control group was administered a placebo, once a day for three months.
To assess the efficacy in relieving depression symptoms, well-established research ratings were evaluated, such as the Hamilton Depression rating scale (HAMD17) and the Clinical Global Impression-Severity scale (CGI-S), for the measurement of symptoms’ severity, as well as the Clinical Global Impression-Improvement scale (CGI-I) scores, for the assessment of improvement or worsening after treatment relative to the baseline state.
The results of the study are very positive for all the different kinds of tests with statistically significant differences between the study group and the control group.
This clinical study confirms the renewed interest of SAMe in the treatment of mood and as adjuvant in depressive symptoms.
A recent review of Sharma et al 2017 has taken into consideration 132 studies - 115 clinical and 17 preclinical – and has provided evidence that oral doses of SAMe are superior to placebo in ameliorating quality of life in depressed people.
To receive more information, please contact firstname.lastname@example.org
We will thank the nutraceutical product tested in the first trial, commercialized by Abela Pharm (Belgrade, Serbia) under the brand name of Tensilen®.